ATS Corp closed its FY2026 on March 31, 2026 with a quarter that simultaneously showcased the most aggressive revenue expansion in the company's history and exposed the costs of pulling that expansion off. Q4 revenue of $747.1M ran 30% above the $574.2M posted a year earlier, while adjusted revenue of $744.3M painted roughly the same picture after stripping out a small amount of purchase accounting noise. On a full-year basis the company crossed well past the $2.5B mark, a scale threshold that resets how the market should think about the platform. The headline revenue beat, however, sits beside a Q4 net loss of $16.2M, narrower than the $68.9M loss from a year ago but still a loss. Adjusted EBITDA of $102.5M improved from $97.1M, but adjusted EPS of $0.36 slipped from $0.41 as integration costs, financing expense, and acquisition-related amortization all worked against the bottom line. Order bookings of $704M offered a more cautious read on momentum than the income statement alone would suggest, and the gap between the topline growth rate and the order growth rate is the single most important fact in this report.
The strategic story is the easier narrative to tell. ATS spent FY2026 repositioning itself from a mid-tier custom automation house into something closer to a global life-sciences and specialty industrial platform. The acquisition of CMA, a process and packaging automation specialist, brought new end markets and a European footprint. The completed integration of the Avantor fluid-handling and single-use bioprocessing business, acquired at the end of FY2025, layered in a consumables and bioprocess equipment franchise that behaves more like a life-sciences tooling vendor than a project-based automator. Smaller bolt-ons filled gaps in food-and-beverage packaging and transportation e-axle assembly. The result is a business with three structural growth engines - life sciences, food and beverage, and transportation - sitting on top of an automation services and aftermarket base that the company continues to scale.
The harder narrative is the one investors have to wrestle with. The acquisitions brought good businesses and they brought a lot of debt. ATS carried roughly $700M of net debt at year-end against an EBITDA base that, while growing, has not yet caught up to the leverage that the deal structure required. Interest expense is a real drag on the P&L. Goodwill and intangibles swelled the balance sheet, and amortization now runs through the income statement at a level that meaningfully distorts GAAP earnings. The GAAP net loss is, in this context, almost a rounding-error figure relative to the cash earnings power of the business, and a skeptical reader has to decide how much of the optical quality of life sciences and the optical weakness of GAAP net income is real.
There are two ways to look at the order intake figure of $704M. The cautious reading is that bookings undershot revenue for the quarter, that the book-to-bill slipped below 1.0, and that the company is converting backlog rather than adding to it. That interpretation would suggest FY2027 starts with a thinner order cushion than the topline growth rate implies. The more constructive reading is that FY2026 was a year of major capital deployment, that customers deferred non-essential orders while integration played out, and that the order book will rebuild through FY2027 as the combined platform goes to market with a unified value proposition. The truth is probably somewhere in the middle, and the next two quarters of order intake are the cleanest read on which way the company is heading.
The investment question, then, is whether the market is pricing ATS for the topline expansion it is delivering or for the leverage and integration friction that the topline expansion is creating. The Q4 result supports both views. A buyer who frames the company as a life-sciences automation consolidator with a multi-year runway sees a name that is exactly executing the strategy that has been laid out. A buyer who frames the company as a balance-sheet stretched, goodwill-heavy, project-based industrial with mediocre order intake sees a name that has traded execution velocity for balance-sheet flexibility. Both buyers look at the same Q4 and reach different conclusions. The next several earnings cycles will do a lot to determine which view the market anchors to, and Q4 FY2026 sits at exactly the moment where neither view has yet won.